ArticleDiabetology & metabolic syndrome2025
Glycaemic control, low levels of high-density lipoprotein, and high cardiovascular risk are associated with cardiovascular autonomic neuropathy.
Article in Diabetology & metabolic syndrome, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Body mass index, sedentary lifestyle, and HbA1c predict cardiac autonomic neuropathy in type 2 diabetes.Cardiovascular diabetology. Endocrinology reports · 2026Article
- Histopathological insights and therapeutic prospects of MCC950 in diabetes-associated autonomic-related structural alterations in a type 1 diabetes Wistar rat model.Diabetology & metabolic syndrome · 2026Article
- The Natural History of Prediabetes and Cardiovascular Disease in the Pediatric Population.Biomedicines · 2026Review
- Association between metabolic dysfunction-associated fatty liver disease and cardiovascular autonomic neuropathy in type 2 diabetes.Frontiers in endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundCardiovascular autonomic neuropathy (CAN) is a life-threatening complication associated with diabetes but may also be present without diabetes. A glycaemic threshold for autonomic impairment is not yet established. The purpose of this study was to compare CAN status in people with and without diabetes and to investigate which factors contributed the most to the presence and severity of CAN.
methodsWe included 240 participants from three different cohorts: non-diabetic people (n = 40), people with overweight or obesity with or without prediabetes (n = 100), and people with type 2 diabetes (n = 100). All participants underwent cardiovascular autonomic reflex tests using the Vagus™ device, and clinical variables, including age, sex, body mass index, blood pressure, HbA1c, blood lipid profile, and cardiovascular risk score, were recorded.
resultsIn total, 14% without and 42% with diabetes had CAN. HbA1c had the most significant influence on CAN scores, with a cutpoint of 45.5 mmol/l corresponding to established prediabetes (sensitivity: 0.66; specificity: 0.71). In people with HbA1c levels below the cutpoint, those with CAN had lower levels of high-density lipoprotein (HDL) (1.1 vs. 1.4 mmol/mol, p = 0.003) and higher cardiovascular risk scores (p < 0.001) compared to people without CAN. No differences in any of the investigated clinical factors were seen between people with HbA1c levels above the cutpoint with or without CAN.
conclusionsIn individuals with HbA1c levels below 45.5 mmol/l, both HDL levels and cardiovascular risk score were associated with CAN status. Therefore, it may be beneficial to screen for CAN in individuals susceptible to prediabetes, who also exhibit low HDL levels and a high cardiovascular risk.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.